Successful crowd funding by FarmPharma via FundedByMe

On June 20 this year, FarmPharma AB started a crowd funding campaign to bring together funding for the company’s further development. Today, 100% of the minimum target has been achieved and more than 50 investors have chosen to invest their money in FarmPharma’s future. The campaign ends at 23:59 on 18/9 2018, or when the maximum funding target is reached.

“We are very pleased that FarmPharma has attracted so much interest among investors,” commented Igor Lokot, CEO of Double Bond Pharmaceutical and FarmPharma, but it is still about 20 days left of the campaign and now we are working intensively to find more investors to reach the maximum funding target – SEK 5 million”.

Invest in FarmPharma through their crowdfunding-campaign

More about crowd funding campaign

More about FarmPharma

FarmPharma AB is a wholly-owned subsidiary of Double Bond Pharmaceutical. The company is active in the development and distribution of veterinary products, and their first product is for the prevention and treatment of bacterial and viral infections in cattle without the use of antibiotics.

More information

See also the press release from 2018-05-14.

Contact information

Full Company Name:  

Double Bond Pharmaceutical International AB (publ)

Corporate identity:      


Stock short name:      


Share ISIN code:        


For more info, contact
Igor Lokot, CEO




Follow us on:

LinkedIn, Facebook and Twitter

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

Share this post